Insider Buying: BlackRock, Inc. (BLK) Director Acquires 1000 Shares of Stock

BlackRock, Inc. (NYSE:BLK) Director William E. Ford bought 1,000 shares of the business’s stock in a transaction dated Thursday, August 2nd.

BlackRock logoBlackRock, Inc. (NYSE:BLK) Director William E. Ford bought 1,000 shares of the business’s stock in a transaction dated Thursday, August 2nd. The shares were bought at an average cost of $467.92 per share, for a total transaction of $467,920.00. Following the transaction, the director now owns 5,400 shares in the company, valued at approximately $2,526,768. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

BlackRock stock opened at $474.15 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 3.87 and a quick ratio of 3.87. BlackRock, Inc. has a one year low of $408.62 and a one year high of $594.52. The stock has a market capitalization of $76.71 billion, a price-to-earnings ratio of 20.98, a price-to-earnings-growth ratio of 1.49 and a beta of 1.61.

BlackRock (NYSE:BLK) last released its quarterly earnings results on Monday, July 16th. The asset manager reported $6.66 EPS for the quarter, beating analysts’ consensus estimates of $6.55 by $0.11. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.58 billion. BlackRock had a return on equity of 13.20% and a net margin of 38.97%. The firm’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $5.24 earnings per share. equities analysts predict that BlackRock, Inc. will post 27.71 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 24th. Shareholders of record on Friday, September 7th will be issued a $3.13 dividend. This is a positive change from BlackRock’s previous quarterly dividend of $2.88. This represents a $12.52 annualized dividend and a yield of 2.64%. The ex-dividend date is Thursday, September 6th. BlackRock’s dividend payout ratio (DPR) is presently 50.97%.

Several equities analysts have commented on the company. JPMorgan Chase & Co. set a $547.00 price objective on BlackRock and gave the company a “buy” rating in a research report on Sunday, July 8th. Citigroup upgraded BlackRock from a “neutral” rating to a “buy” rating in a report on Monday, June 18th. Morgan Stanley lowered their target price on BlackRock from $624.00 to $607.00 and set an “overweight” rating for the company in a report on Thursday, July 12th. Keefe, Bruyette & Woods upgraded BlackRock from a “market perform” rating to an “outperform” rating and set a $590.00 target price for the company in a report on Friday, July 13th. Finally, Barclays lowered their target price on BlackRock from $615.00 to $595.00 and set an “overweight” rating for the company in a report on Tuesday, July 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $594.25.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in BlackRock by 2.1% in the second quarter. BlackRock Inc. now owns 7,601,685 shares of the asset manager’s stock valued at $3,793,546,000 after purchasing an additional 153,749 shares during the period. Summit Trail Advisors LLC lifted its position in shares of BlackRock by 53,902.3% in the first quarter. Summit Trail Advisors LLC now owns 1,274,454 shares of the asset manager’s stock valued at $1,274,000 after acquiring an additional 1,272,094 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of BlackRock by 2.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 476,036 shares of the asset manager’s stock valued at $237,562,000 after acquiring an additional 12,785 shares in the last quarter. Royal Bank of Canada lifted its position in shares of BlackRock by 6.9% in the first quarter. Royal Bank of Canada now owns 452,599 shares of the asset manager’s stock valued at $245,183,000 after acquiring an additional 29,222 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in shares of BlackRock by 1.5% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 448,835 shares of the asset manager’s stock valued at $243,142,000 after acquiring an additional 6,507 shares in the last quarter. 84.12% of the stock is currently owned by institutional investors.

BlackRock Company Profile

BlackRock, Inc is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.

Featured Story: Trading Strategy Methods for Individual Investors

Insider Buying and Selling by Quarter for BlackRock (NYSE:BLK)

Receive News & Ratings for BlackRock Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BlackRock and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Altman Advisors Inc. Purchases 183406 Shares of BlackRock, Inc. (NYSE:BLK)

Altman Advisors Inc. grew its position in shares of BlackRock, Inc. (NYSE:BLK) by 3,276.3% during the second quarter, according to its most recent …

BlackRock logoAltman Advisors Inc. grew its position in shares of BlackRock, Inc. (NYSE:BLK) by 3,276.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 189,004 shares of the asset manager’s stock after purchasing an additional 183,406 shares during the quarter. BlackRock makes up 2.0% of Altman Advisors Inc.’s holdings, making the stock its 20th biggest holding. Altman Advisors Inc. owned approximately 0.12% of BlackRock worth $2,140,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BLK. Summit Trail Advisors LLC boosted its stake in shares of BlackRock by 53,902.3% during the first quarter. Summit Trail Advisors LLC now owns 1,274,454 shares of the asset manager’s stock valued at $1,274,000 after purchasing an additional 1,272,094 shares in the last quarter. FIL Ltd boosted its stake in shares of BlackRock by 386.0% during the first quarter. FIL Ltd now owns 322,223 shares of the asset manager’s stock valued at $174,555,000 after purchasing an additional 255,927 shares in the last quarter. BlackRock Inc. boosted its stake in shares of BlackRock by 2.6% during the first quarter. BlackRock Inc. now owns 7,447,936 shares of the asset manager’s stock valued at $4,034,698,000 after purchasing an additional 192,139 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new stake in shares of BlackRock during the second quarter valued at about $377,000. Finally, Bessemer Group Inc. boosted its stake in shares of BlackRock by 6,346.5% during the second quarter. Bessemer Group Inc. now owns 183,724 shares of the asset manager’s stock valued at $91,685,000 after purchasing an additional 180,874 shares in the last quarter. 84.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently commented on the company. JPMorgan Chase & Co. reissued a “focus list” rating and set a $547.00 price target on shares of BlackRock in a research note on Monday, July 2nd. Keefe, Bruyette & Woods raised BlackRock from a “market perform” rating to an “outperform” rating and set a $590.00 price target on the stock in a research note on Friday, July 13th. Goldman Sachs Group cut their price target on BlackRock to $570.00 and set a “buy” rating on the stock in a research note on Tuesday, July 17th. ValuEngine lowered BlackRock from a “buy” rating to a “hold” rating in a research note on Friday, June 15th. Finally, Deutsche Bank cut their price target on BlackRock from $570.00 to $561.00 and set a “buy” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $594.25.

BlackRock stock opened at $474.15 on Friday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $76.71 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.49 and a beta of 1.61. BlackRock, Inc. has a one year low of $408.62 and a one year high of $594.52.

BlackRock (NYSE:BLK) last posted its quarterly earnings data on Monday, July 16th. The asset manager reported $6.66 EPS for the quarter, topping the Zacks’ consensus estimate of $6.55 by $0.11. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.58 billion. BlackRock had a return on equity of 13.20% and a net margin of 38.97%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $5.24 earnings per share. equities analysts predict that BlackRock, Inc. will post 27.71 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 24th. Investors of record on Friday, September 7th will be paid a $3.13 dividend. This is a positive change from BlackRock’s previous quarterly dividend of $2.88. This represents a $12.52 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend is Thursday, September 6th. BlackRock’s payout ratio is currently 50.97%.

In other BlackRock news, insider Jeff A. Smith sold 166 shares of BlackRock stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $546.13, for a total value of $90,657.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William E. Ford bought 1,000 shares of the stock in a transaction on Thursday, August 2nd. The stock was acquired at an average price of $467.92 per share, with a total value of $467,920.00. Following the completion of the acquisition, the director now owns 5,400 shares of the company’s stock, valued at approximately $2,526,768. The disclosure for this purchase can be found here. 1.75% of the stock is owned by insiders.

BlackRock Company Profile

BlackRock, Inc is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.

Recommended Story: Investing in Growth Stocks

Institutional Ownership by Quarter for BlackRock (NYSE:BLK)

Receive News & Ratings for BlackRock Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BlackRock and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Purchases New Holdings in Cardlytics Inc (NASDAQ:CDLX)

BlackRock Inc. acquired a new position in Cardlytics Inc (NASDAQ:CDLX) in the 1st quarter, according to its most recent 13F filing with the Securities …

Cardlytics logoBlackRock Inc. acquired a new position in Cardlytics Inc (NASDAQ:CDLX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 233,836 shares of the company’s stock, valued at approximately $3,420,000. BlackRock Inc. owned approximately 1.17% of Cardlytics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CDLX. Frontier Capital Management Co. LLC purchased a new position in Cardlytics during the first quarter valued at approximately $148,000. Wells Fargo & Company MN acquired a new stake in shares of Cardlytics during the first quarter worth $305,000. Dean Capital Investments Management LLC acquired a new stake in shares of Cardlytics during the first quarter worth $438,000. Northern Trust Corp acquired a new stake in shares of Cardlytics during the first quarter worth $840,000. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in shares of Cardlytics during the first quarter worth $892,000. Hedge funds and other institutional investors own 49.41% of the company’s stock.

A number of research analysts recently issued reports on the stock. Bank of America restated a “hold” rating and set a $22.00 target price on shares of Cardlytics in a research report on Friday. KeyCorp decreased their price objective on shares of Cardlytics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Gabelli reaffirmed a “buy” rating on shares of Cardlytics in a research note on Monday, April 23rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $24.00.

NASDAQ CDLX opened at $20.62 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $401.64 million and a P/E ratio of -2.57. Cardlytics Inc has a 12 month low of $11.10 and a 12 month high of $25.71.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, August 14th. The company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.32. The company had revenue of $35.57 million during the quarter, compared to analysts’ expectations of $34.89 million. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. research analysts forecast that Cardlytics Inc will post -1.97 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company’s platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: Price to Earnings Ratio (PE) Basics

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cardlytics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

ConforMIS Inc (CFMS) Shares Bought by BlackRock Inc.

BlackRock Inc. lifted its stake in ConforMIS Inc (NASDAQ:CFMS) by 2.6% in the 1st quarter, according to its most recent filing with the Securities and …

ConforMIS logoBlackRock Inc. lifted its stake in ConforMIS Inc (NASDAQ:CFMS) by 2.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,398,722 shares of the medical instruments supplier’s stock after purchasing an additional 61,539 shares during the period. BlackRock Inc. owned 3.94% of ConforMIS worth $3,478,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CFMS. Two Sigma Investments LP acquired a new stake in ConforMIS in the 4th quarter valued at approximately $130,000. Schwab Charles Investment Management Inc. raised its position in ConforMIS by 93.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 140,943 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 68,000 shares during the last quarter. Deutsche Bank AG raised its position in ConforMIS by 43.5% in the 4th quarter. Deutsche Bank AG now owns 120,849 shares of the medical instruments supplier’s stock valued at $286,000 after buying an additional 36,634 shares during the last quarter. Northern Trust Corp raised its position in ConforMIS by 20.2% in the 1st quarter. Northern Trust Corp now owns 538,985 shares of the medical instruments supplier’s stock valued at $782,000 after buying an additional 90,447 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in ConforMIS by 627.0% in the 4th quarter. Renaissance Technologies LLC now owns 346,800 shares of the medical instruments supplier’s stock valued at $825,000 after buying an additional 299,100 shares during the last quarter. Hedge funds and other institutional investors own 42.60% of the company’s stock.

CFMS has been the topic of several recent analyst reports. ValuEngine raised ConforMIS from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. BTIG Research reaffirmed a “buy” rating and set a $3.00 price target on shares of ConforMIS in a research report on Thursday, May 3rd. Oppenheimer set a $4.00 price target on ConforMIS and gave the stock a “buy” rating in a research report on Thursday, May 3rd. Zacks Investment Research raised ConforMIS from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Wednesday, June 20th. Finally, SunTrust Banks reiterated a “buy” rating on shares of ConforMIS in a research note on Monday, July 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $3.25.

CFMS opened at $0.91 on Friday. The firm has a market capitalization of $61.28 million, a P/E ratio of -0.73 and a beta of 0.90. ConforMIS Inc has a 1 year low of $0.88 and a 1 year high of $4.17. The company has a quick ratio of 4.15, a current ratio of 4.77 and a debt-to-equity ratio of 0.60.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Friday, August 3rd. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $19.52 million. ConforMIS had a negative net margin of 64.66% and a negative return on equity of 94.69%. research analysts expect that ConforMIS Inc will post -0.83 EPS for the current fiscal year.

ConforMIS Company Profile

ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Featured Story: Market Capitalization

Institutional Ownership by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ConforMIS and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Amalgamated Bank Increases Position in Healthequity Inc (HQY)

WINTON GROUP Ltd bought a new stake in shares of Healthequity in the first quarter worth about $206,000. Finally, Parametrica Management Ltd …

Healthequity logoAmalgamated Bank lifted its position in Healthequity Inc (NASDAQ:HQY) by 21.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,792 shares of the company’s stock after purchasing an additional 1,534 shares during the quarter. Amalgamated Bank’s holdings in Healthequity were worth $660,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of HQY. Citigroup Inc. increased its holdings in shares of Healthequity by 414.4% in the first quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock worth $160,000 after purchasing an additional 2,126 shares during the last quarter. Cim LLC bought a new stake in shares of Healthequity in the second quarter worth about $204,000. M&T Bank Corp bought a new stake in shares of Healthequity in the first quarter worth about $206,000. WINTON GROUP Ltd bought a new stake in shares of Healthequity in the first quarter worth about $206,000. Finally, Parametrica Management Ltd bought a new stake in shares of Healthequity in the first quarter worth about $220,000. 95.38% of the stock is currently owned by hedge funds and other institutional investors.

In other Healthequity news, VP Darcy G. Mott sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $73.93, for a total transaction of $702,335.00. Following the completion of the transaction, the vice president now owns 111,500 shares in the company, valued at $8,243,195. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frank Medici sold 6,904 shares of the business’s stock in a transaction that occurred on Friday, July 13th. The shares were sold at an average price of $80.40, for a total value of $555,081.60. Following the transaction, the director now owns 17,649 shares of the company’s stock, valued at approximately $1,418,979.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,100 shares of company stock valued at $4,457,965. 4.00% of the stock is currently owned by company insiders.

Several brokerages have recently issued reports on HQY. KeyCorp lifted their target price on Healthequity from $82.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, July 19th. Zacks Investment Research raised Healthequity from a “sell” rating to a “hold” rating in a report on Friday, July 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $68.00 target price (up from $65.00) on shares of Healthequity in a report on Monday, June 4th. ValuEngine upgraded Healthequity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 22nd. Finally, SunTrust Banks lifted their price target on Healthequity from $70.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, June 5th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $77.73.

HQY opened at $87.05 on Friday. The stock has a market capitalization of $5.12 billion, a P/E ratio of 161.78, a P/E/G ratio of 3.43 and a beta of 1.37. Healthequity Inc has a 12 month low of $40.21 and a 12 month high of $88.30.

Healthequity (NASDAQ:HQY) last released its quarterly earnings results on Monday, June 4th. The company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.09. The company had revenue of $69.90 million during the quarter, compared to analyst estimates of $68.81 million. Healthequity had a return on equity of 13.47% and a net margin of 22.91%. The firm’s revenue was up 26.2% on a year-over-year basis. During the same quarter last year, the business posted $0.23 earnings per share. analysts expect that Healthequity Inc will post 0.72 EPS for the current year.

About Healthequity

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Further Reading: Diversification in Your Portfolio

Institutional Ownership by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Healthequity and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts